SCHEMBL3428774

SCHEMBL3428774

NCC1CC[N]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL664855 0.79
SCHEMBL665954 0.79
SCHEMBL666880 0.79
SCHEMBL945485 0.77
SCHEMBL2920290 0.72
SCHEMBL2914362 0.69 NCF1 (0.50)
SCHEMBL10692178 0.64
SCHEMBL957744 0.62
SCHEMBL948954 0.62
SCHEMBL2439571 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912721-B2 Fused pentacyclic imidazole derivatives UCB Biopharma SRL (BE) 2024-02-27 US disclosed
EP-3740478-B1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2023-11-01 EP disclosed
US-11472794-B2 Fused imidazole derivatives as IL-17 modulators UCB Biopharma SRL (BE) 2022-10-18 US disclosed
US-20220227764-A1 Imidazopyridine Derivatives as IL-17 Modulators UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) 2022-07-21 US disclosed
CN-109195968-B Fused pentacyclic imidazole derivatives as modulators of TNF activity UCB生物制药私人有限公司 2022-02-11 CN disclosed
CN-114026084-A Fused imidazole derivatives as IL-17 modulators UCB生物制药有限责任公司 2022-02-08 CN disclosed
CN-109219609-B Fused hexacyclic imidazole derivatives as modulators of TNF activity UCB生物制药私人有限公司 2022-02-01 CN disclosed
CN-113906025-A Imidazopyridine derivatives as IL-17 modulators UCB生物制药有限责任公司 2022-01-07 CN disclosed
CN-109195969-B Fused pentacyclic imidazole derivatives as modulators of TNF activity UCB生物制药私人有限公司 2021-12-21 CN disclosed
CN-109219608-B Fused pentacyclic imidazole derivatives as modulators of TNF activity UCB生物制药私人有限公司 2021-12-21 CN disclosed
WO-2009093009-A1 FUSED TRICYCLIC THIOPHENE DERIVATIVES AS MEK INHIBITORS UCB PHARMA S.A. (BE) 2009-07-30 WO disclosed
EP-2032140-A1 PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2009-03-11 EP disclosed
WO-2007138355-A1 PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-12-06 WO disclosed
US-20070197501-A1 Use Of Chemotherapeutic Agents BAYER INNOVATION GMBH (DE) 2007-08-23 US disclosed
EP-1408034-B1 Use of Quinolone and Quinolizinone derivatives as chemotherapeutic agents SCHULZ & SCHLIMBACH GBR (DE) 2007-08-08 EP disclosed
EP-1408034-A1 Use of Quinoline derivatives as antibacterial agents Schulz &amp; Schlimbach GbR (DE) 2004-04-14 EP disclosed
EP-1244434-B1 USE OF CHEMOTHERAPEUTIC AGENTS SCHULZ & SCHLIMBACH GBR (DE) 2004-03-17 EP disclosed
US-20030045544-A1 Bactericides for the oral region of animals using 3-carboxy-4-oxo quinoline or 1,8-naphthyridine derivatives or 1-cyclopropyl-3-carboyx-4-oxo quinolizine derivatives BAYER INNOVATION GMBH (DE) 2003-03-06 US disclosed
EP-1244434-A2 USE OF CHEMOTHERAPEUTIC AGENTS Schulz, Hans-Herrmann (DE) 2002-10-02 EP disclosed
WO-2001045679-A2 USE OF CHEMOTHERAPEUTIC AGENTS FOR TOPICAL TREATMENT SCHULZ HANS HERRMANN (DE) 2001-06-28 WO disclosed